Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis

Rubeshan Perumal; Neda Bionghi; Camus Nimmo; Marothi Letsoalo; Matthew J Cummings; Madeleine Hopson; Allison Wolf; Shamim Al Jubaer; Nesri Padayatchi; Kogieleum Naidoo; Michelle H Larsen; Max O'Donnell

doi:10.1183/13993003.00639-2023

Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis

Eur Respir J. 2023 Dec 14;62(6):2300639. doi: 10.1183/13993003.00639-2023. Print 2023 Dec.

Authors

Rubeshan Perumal^{1

2

3}, Neda Bionghi^{4

3}, Camus Nimmo⁵, Marothi Letsoalo⁶, Matthew J Cummings⁷, Madeleine Hopson⁴, Allison Wolf⁷, Shamim Al Jubaer⁸, Nesri Padayatchi⁶, Kogieleum Naidoo⁶, Michelle H Larsen^{8

3}, Max O'Donnell^{6

7

9

3}

Affiliations

¹ CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa rubeshanperumal@gmail.com.
² Division of Pulmonology and Critical Care, Department of Medicine, University of KwaZulu-Natal, Durban, South Africa.
³ These authors contributed equally to this work.
⁴ Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
⁵ Francis Crick Institute, London, UK.
⁶ CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
⁷ Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
⁸ Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
⁹ Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.

Abstract

Bedaquiline resistance is a major threat to drug-resistant tuberculosis control strategies. This analysis found a pooled prevalence of baseline bedaquiline resistance of 2.4% and a pooled prevalence of treatment-emergent bedaquiline resistance of 2.1%. https://bit.ly/3FC6yio

Publication types

Meta-Analysis
Systematic Review
Letter

MeSH terms

Antitubercular Agents / therapeutic use
Diarylquinolines / therapeutic use
Humans
Mycobacterium tuberculosis*
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

bedaquiline
Diarylquinolines
Antitubercular Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding